Yissum - Research Development Company of the Hebrew University

Big-data Computational Tool for Patient-Specific Cancer Therapy

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cluster7
Cluster8

From big data analysis to personalized medicine in cancer:
towards the development of a computational tool for the rational design of patient-specific combination therapy.
Project ID : 10-2016-4322

Yissum - Research Development Company of the Hebrew University

Description of the technology

Category

Medical Device, BioInformatics, Oncology/Cancer

Highlights

This technology provides a way to design patient-specific drug combinations through an accurate tumor classification, such that every single tumor can be mapped precisely and unambiguously according to the molecular aberrations that it harbors.

Our Innovation 

  • Addressing individual patients, in the opposite to conventional statistical analysis method relating to pre-defined categories of the patient population
  • Once the information from multiple patients is transformed into a low-dimensional space, the technology can provide patient-specific unbalanced network structures. These structures can be used to rationally design patient specific drug therapies.
  • Prediction of direction change in biological systems, thereby generating rationalized strategies for the manipulation of their phenotypes.

Technology

The developed algorithm allows to decoding of altered molecules as well as the structure of the altered molecular networks in each tumor. Specifically, the patient-specific signaling signature, representing the flow of cellular information. The algorithm predicts drug combinations that will target particular components of these networks, in order to restore balance, and correct the tissues, preferentially by killing the tumor cell.

 

Algorithm Workflow

Opportunity

  • Accurate resolution of patient-specific network structures, or a patient-specific signaling protein network signature.
  • The algorithm helps clinicians to rationally design patient-specific drug combinations. Inhibition of the entire set of tumor-specific processes should stop the disease and significantly decrease the chances for the development of drug resistance.

Current development stage

TRL 5 – Alpha testing for of the software by in-house developers/testers

The plan is to extend the approach above to additional cancer types, in vivo animal models and patient derived cancer tissues.

 

Project manager

Ariela Markel
VP, Business Development, Healthcare

Project researchers

Nataly Kravchenko-Balasha
HUJI, Faculty of Dental Medicine
Institute of Dental Sciences

Related keywords

  • Information Processing, Information System, Workflow Management
  • IT and Telematics Applications
  • Multimedia
  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Computers
  • Computer Graphics Related
  • Specialised Turnkey Systems
  • Scanning Related
  • Peripherals
  • Computer Services
  • Computer Software Market
  • Other Computer Related
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • bioinformatics
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.